AKT1 and cancer: Although the specific mechanism of CIP2A transcription suppression is yet to be reported, this is of great interest as CIP2A repression and subsequent upregulation of PP2A activity in key cancer-promoting pathways (such as Akt and c-myc) affects the sensitivity of these solid tumors to bortezomib.